Plasma microRNA biomarkers for detection of mild cognitive impairment

Early stages of many neurodegenerative diseases, such as Alzheimer's disease, vascular and frontotemporal dementia, and Parkinson's disease, are frequently associated with Mild Cognitive Impairment (MCI). A minimally invasive screening test for early detection of MCI may be used to select optimal patient groups in clinical trials, to monitor disease progression and response to treatment, and to better plan patient clinical care. Here, we examined the feasibility of using pairs of brain-enriched plasma microRNA (miRNA), at least one of which is enriched in synapses and neurites, as biomarkers that could differentiate patients with MCI from age-matched controls. The identified biomarker pairs fall into two sets: the “miR-132 family” (miR-128/miR-491-5p, miR-132/miR-491-5p and mir-874/miR-491-5p) and the “miR-134 family” (miR-134/miR-370, miR-323-3p/miR-370 and miR-382/miR-370). The area under the Receiver-Operating Characteristic curve for the differentiation of MCI from controls using these biomarker pairs is 0.91-0.95, with sensitivity and specificity at 79%-100% (miR-132 family) and 79%-95% (miR-134 family), and p < 0.001. In a separate longitudinal study, the identified miRNA biomarker pairs successfully detected MCI in majority of patients at asymptomatic stage 1-5 years prior to clinical diagnosis. The reported biomarker pairs also appear useful for detecting age-related brain changes. Further testing in a larger study is necessary for validation of these results.

[1]  Axel Benner,et al.  Circulating microRNAs in plasma as early detection markers for breast cancer , 2013, International journal of cancer.

[2]  D. V. Vactor,et al.  MicroRNAs Shape the Neuronal Landscape , 2012, Neuron.

[3]  F. Slack,et al.  Novel MicroRNAs Differentially Expressed during Aging in the Mouse Brain , 2012, PloS one.

[4]  A. Adai,et al.  miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts , 2012, Clinical Cancer Research.

[5]  Michael F. Ochs,et al.  Serum microRNA Biomarkers for Detection of Non-Small Cell Lung Cancer , 2012, PloS one.

[6]  A. Dejean,et al.  Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells , 2012, Nature Cell Biology.

[7]  L. Goff,et al.  Expression profiling of synaptic microRNAs from the adult rat brain identifies regional differences and seizure-induced dynamic modulation , 2012, Brain Research.

[8]  F. Slack,et al.  MicroRNAs and their roles in aging , 2012, Journal of Cell Science.

[9]  A. Budovsky,et al.  Molecular links between cellular senescence, longevity and age-related diseases – a systems biology perspective , 2011, Aging.

[10]  E. Wang,et al.  Circulatory miR-34a as an RNA-based, noninvasive biomarker for brain aging , 2011, Aging.

[11]  B. Schmand,et al.  Value of Neuropsychological Tests, Neuroimaging, and Biomarkers for Diagnosing Alzheimer's Disease in Younger and Older Age Cohorts , 2011, Journal of the American Geriatrics Society.

[12]  A. Fagan,et al.  Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. , 2011, Archives of neurology.

[13]  R. Nagele,et al.  Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera , 2011, PloS one.

[14]  R. Nagele,et al.  Diagnosis of Alzheimer's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera , 2011, PloS one.

[15]  C. Luis,et al.  Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid , 2011, International journal of Alzheimer's disease.

[16]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[17]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[18]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[19]  A. Nakamura,et al.  Identification of Muscle-Specific MicroRNAs in Serum of Muscular Dystrophy Animal Models: Promising Novel Blood-Based Markers for Muscular Dystrophy , 2011, PloS one.

[20]  G. Schratt microRNAs at the synapse , 2011, Nature Reviews Cancer.

[21]  J O Rinne,et al.  Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.

[22]  A. Brunet,et al.  The microRNA cluster miR-106b~25 regulates adult neural stem/progenitor cell proliferation and neuronal differentiation , 2011, Aging.

[23]  D. DiMaio,et al.  MicroRNAs and senescence , 2011, Aging.

[24]  D. German,et al.  Identification of Candidate IgG Biomarkers for Alzheimer's Disease via Combinatorial Library Screening , 2011, Cell.

[25]  Eric Lai,et al.  MicroRNA-Related Cofilin Abnormality in Alzheimer's Disease , 2010, PloS one.

[26]  David A Loewenstein,et al.  Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions , 2010, Alzheimer's Research & Therapy.

[27]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[28]  S. Moebus,et al.  Prevalence of mild cognitive impairment and its subtypes in the Heinz Nixdorf Recall study cohort , 2010, Alzheimer's & Dementia.

[29]  D. Alkon,et al.  Early diagnostic accuracy and pathophysiologic relevance of an autopsy-confirmed Alzheimer's disease peripheral biomarker , 2010, Neurobiology of Aging.

[30]  Amity E. Green,et al.  3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI , 2010, Human brain mapping.

[31]  E. Masliah,et al.  Molecular mechanisms of neurodegeneration in Alzheimer's disease. , 2010, Human molecular genetics.

[32]  P. Provost,et al.  Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases , 2010, Aging.

[33]  Wenyaw Chan,et al.  Predicting progression of Alzheimer's disease , 2010, Alzheimer's Research & Therapy.

[34]  Yi Li,et al.  Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies , 2009, Journal of clinical neurology.

[35]  Greg Miller,et al.  Alzheimer's biomarker initiative hits its stride. , 2009, Science.

[36]  Duolao Wang,et al.  Serum Aβ Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort , 2009, Molecular medicine.

[37]  Carole Dufouil,et al.  Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND) , 2009, Alzheimer's Research & Therapy.

[38]  D. Bredesen Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence , 2009, Molecular Neurodegeneration.

[39]  Lu Xie,et al.  Identification and target prediction of miRNAs specifically expressed in rat neural tissue , 2009, BMC Genomics.

[40]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[41]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[42]  John O. Willis,et al.  Wechsler Adult Intelligence Scale–Third Edition , 2008 .

[43]  Vetle I. Torvik,et al.  Expression of microRNAs and their precursors in synaptic fractions of adult mouse forebrain , 2008, Journal of neurochemistry.

[44]  T. Luck,et al.  [Mild cognitive impairment and development of dementia]. , 2008, Psychiatrische Praxis.

[45]  Heidi J. Peltier,et al.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. , 2008, RNA.

[46]  Yuriy Gusev,et al.  Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. , 2007, RNA.

[47]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[48]  W. Chan,et al.  Importance of Subtle Amnestic and Nonamnestic Deficits in Mild Cognitive Impairment: Prognosis and Conversion to Dementia , 2007, Dementia and Geriatric Cognitive Disorders.

[49]  Sasha F. Levy,et al.  Somatodendritic microRNAs identified by laser capture and multiplex RT-PCR. , 2007, RNA.

[50]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[51]  Yu Liang,et al.  BMC Genomics , 2007 .

[52]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[53]  Hwai-Jong Cheng,et al.  Axon pruning: an essential step underlying the developmental plasticity of neuronal connections , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[54]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[55]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[56]  C. Ko,et al.  Pruning an Axon Piece by Piece A New Mode of Synapse Elimination , 2004, Neuron.

[57]  Jeff W. Lichtman,et al.  Axon Branch Removal at Developing Synapses by Axosome Shedding , 2004, Neuron.

[58]  H. Amièva,et al.  Incidence and outcome of mild cognitive impairment in a population-based prospective cohort , 2002, Neurology.

[59]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[60]  N. Butters,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.

[61]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[62]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[63]  D. O’Carroll,et al.  General Principals of miRNA Biogenesis and Regulation in the Brain , 2013, Neuropsychopharmacology.

[64]  J. Satoh MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains. , 2010, Journal of pharmacological sciences.

[65]  W. Markesbery,et al.  Neuropathologic alterations in mild cognitive impairment: a review. , 2010, Journal of Alzheimer's disease : JAD.

[66]  V. Nimmrich,et al.  Is Alzheimer's Disease a Result of Presynaptic Failure? - Synaptic Dysfunctions Induced by Oligomeric β-Amyloid , 2009, Reviews in the neurosciences.

[67]  A. Roses,et al.  Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways , 2008 .

[68]  Patrizia Mecocci,et al.  Mild cognitive impairment: a systematic review. , 2007, Journal of Alzheimer's disease : JAD.

[69]  G. Davis,et al.  Synapse disassembly. , 2003, Genes & development.

[70]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[71]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[72]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[73]  J. Eng,et al.  Sample Size Estimation : How Many Individuals Should Be Studied ? , 2022 .